statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Coherus Biosciences price target lowered by $2 at H.C. Wainwright, here's why

Investors eyeing a purchase of Coherus BioSciences Inc (CHRS) shares, but cautious about paying the going market price of 2.37/share, might benefit from considering selling puts among the...

Commit To Purchase Coherus BioSciences At $2, Earn 42.6% Annualized Using Options

Q4 2023 Coherus BioSciences Inc Earnings Call Transcript

Company Focuses on Oncology and Launches New Products Amidst RestructuringRelated Stocks: CHRS...

Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...

Coherus Biosciences reports Q4 EPS (62c), consensus (12c)

Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 UDENYCA net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 CIMERLI net...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ( Coherus, NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be...

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Upfront cash payment of $170 million strengthens capital structure Transaction solidifies Coherus' strategic focus in oncology REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE...

Coherus Completes Divestiture of Ophthalmology Franchise

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ( Coherus or the Company , Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation...

Coherus BioSciences Announces New Employment Inducement Grants

Coherus Biosciences announces U.S. launch of UDENYCA ONBODY

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Volume	907,176.00
52-Wk High	$8.22
52-Wk Low	$1.43

CHRS Coherus Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals